Ratings
0
Nobody has rated this yet. Be the first!
Works
3
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
Lists
0
.png/500px-American_Academy_of_Arts_and_Sciences_(ancient_logo).png)
